Ardelyx Inc (NAS:ARDX)
$ 4.925 -0.145 (-2.86%) Market Cap: 1.17 Bil Enterprise Value: 1.12 Bil PE Ratio: 0 PB Ratio: 7.35 GF Score: 75/100

Ardelyx Inc FDA Advisory Committee Update Call Transcript

Nov 17, 2022 / 01:00PM GMT
Release Date Price: $1.72 (+40.98%)
Operator

Good morning, and welcome to Ardelyx conference call. (Operator Instructions) Today's conference title is FDA Advisory Committee update. (Operator Instructions) As a reminder, today's conference call is being recorded. At this time, I would like to turn the conference call over to (inaudible), Vice President, Corporate Communications and Investor Relations. You may begin.

Unidentified Company Representative

Thank you, and good morning, everyone. Last night, we issued a press release announcing the positive outcome of the FDA and Committee meetings for XPHOZAH. During this call, we will refer to yesterday's press release, which is available on the Investors section of the company's website at ardelyx.com. .

On the call with me today with prepared remarks are Mike Raab, President and CEO; Dr. Laura Williams, Chief Medical Officer; and Susan Rodriguez, Chief Commercial Officer. Justin Renz, Chief Financial Officer; Rob Blanks; Chief Regulatory Affairs and Quality Assurance Officer; and David Rosenbaum, Chief Development Officer, will join us for the question-and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot